# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> Collagen content and myofiber size corresponded to reduced whole muscle cellular senescence and SASP markers.

## Panel reviews

### `evidence_auditor` — `reject` (score 1)

The submission contains a critical failure in the citation trace for claim C013. The alias match for 'Collagen' resolved to 'CAPTOPRIL', which is a completely different pharmacological agent and unrelated to the structural protein collagen. This indicates a fundamental failure in the evidence trace, as the claim regarding collagen content is being supported by data pertaining to a different drug.

**Flagged claims:** C013

### `domain_skeptic` — `reject` (score 2)

The submission contains a critical domain error and a fundamental failure in evidence mapping. The alias match for C013 resolves 'Collagen' to 'CAPTOPRIL'. Captopril is an ACE inhibitor, not a structural protein or a marker of fibrosis. This indicates a complete hallucination or a catastrophic failure in the data pipeline where a drug name is being substituted for a biological marker. Consequently, the claim that collagen content corresponds to reduced senescence is unsupported by the provided trace.

Furthermore, the claims rely on a single reference [6] to support three distinct mechanistic outcomes (myofiber atrophy, SASP markers, and FAP senescence). Without seeing the study design, the leap from 'metformin-treated individuals' (C012) to 'primary muscle resident fibro-adipogenic progenitors' (C014) suggests a mix of in vivo and in vitro data that is being conflated into a single narrative of human muscle preservation. The scope is over-extended and the biological entities are misidentified.

**Flagged claims:** C013, C014

### `final_judge` — `reject` (score 1)

The submission suffers from a catastrophic failure in the evidence mapping process. Both the Evidence Auditor and the Domain Skeptic correctly identified a critical error in the citation trace for C013, where the biological structural protein 'Collagen' was erroneously aliased to 'CAPTOPRIL', an ACE inhibitor. This is not a minor nuance but a fundamental hallucination in the data pipeline that invalidates the supporting evidence for the thesis. 

I concur with the Domain Skeptic's observation that the reliance on a single reference [6] to bridge disparate biological levels—from whole-muscle atrophy in individuals to specific markers in primary FAPs—without clear distinction between in vivo and in vitro results further undermines the reliability of the claims. Given the identity error regarding collagen, the entire mechanistic chain is compromised.

**Flagged claims:** C013, C014
